Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …

Purpose To investigate if cetuximab induces epithelial to mesenchymal transition (EMT) and
activation of cancer associated fibroblast (CAF) in the tumors of patients with squamous cell …

Cetuximab is the single targeted therapy approved for the treatment of head and neck
cancer (HNSCC). Predictive biomarkers have not been established and patient stratification …

A growing body of evidence suggests that components of the tumor microenvironment,
including cancer-associated fibroblasts (CAF), may modulate the treatment sensitivity of …

Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head
and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of …

Background Identifying potential resistance mechanisms while tumour cells still respond to
therapy is critical to delay acquired resistance. Methods We generated the first …

The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a
variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been …

Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-
targeting drug cetuximab poses a challenge to their effective clinical management. Here, we …

Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is
used in cancer treatment. Although development of resistance to cetuximab is well …

The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck
squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as …